 phase pharmacokinetics polyethylene glycol soluble formulation recombinant prolonged half-life routes schedules administration patient comfort covalent attachment polyethylene glycol analog preclinical data characteristics biologic activity report phase maximum dose polyethylene glycol biologic activity prolonged half-life vivo Sixty-six patients study months Polyethylene week minutes maximum dose pattern toxicity similar parent compound patients evidence tumor regression partial remission minor response pharmacokinetic data prolongation half-life recombinant neutralizing antibodies study sufficient impetus ongoing phase II studies polyethylene glycol